


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo
英矽智能

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 3696)

VOLUNTARY ANNOUNCEMENT
AI EMPOWERS REGIONAL DRUG DISCOVERY: INSILICO MEDICINE'S
UAE TEAM NOMINATES ITS FIRST PRECLINICAL CANDIDATE DRUG

This announcement is made by InSilico Medicine Cayman TopCo (the “**Company**”, together with its subsidiaries, the “**Group**” or “**Insilico Medicine**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that Insilico Medicine has officially nominated **ISM0387**, an MTA-cooperative PRMT5 inhibitor, as a pre-clinical candidate (PCC). Discovered locally by Insilico Medicine’s UAE team using the Company’s proprietary Pharma.AI platform, the program completed the early discovery workflow – from molecular design to optimization – in the UAE within less than 12 months, during which a series of hit compounds was generated within 30 days, followed by the completion of lead compound optimization within 6 months.

ISM0387 is an MTA-cooperative PRMT5 inhibitor with AI-powered novel structure, showing improved *in vitro* activity and selectivity, enhanced brain penetrant properties, and robust, dose-dependent efficacy in disease models. Featuring novel structure and exceptional CNS-penetrant abilities, ISM0387 offers a promising new treatment option for patients with Glioblastoma (GBM).

This nomination also represents Insilico Medicine’s 30th AI-supported pre-clinical candidate (PCC) to date. The announcement of this achievement was witnessed and supported by the Emirates Drug Establishment (EDE), the Department of Health (DoH) – Abu Dhabi, and the Abu Dhabi Investment Office (ADIO).

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, April 24, 2026

As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Kan Chen, Ph.D., Mr. Chuen Yan Leung, Ph.D., and Mr. Long Shi as non-executive directors; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.